PRODUCT INFORMATION

LB 42708

Item No. 16428

CAS Registry No.:	226929-39-1
Formal Name:	[1-[[1-[(4-bromophenyl)methyl]-1H-imidazol-5-yl]methyl]-4-(1-naphthalenyl)-1H-pyrrol-3-yl]-4-morpholinyl-methanone
MF:	$C_{30}H_{27}BrN_4O_2$
FW:	555.5
Purity:	≥98%
UV/Vis.:	λ_{max}: 223, 296 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LB 42708 is supplied as a crystalline solid. A stock solution may be made by dissolving the LB 42708 in the solvent of choice, which should be purged with an inert gas. LB 42708 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of LB 42708 in these solvents is approximately 30 mg/ml.

LB 42708 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, LB 42708 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. LB 42708 has a solubility of approximately 0.1 mg/ml in a 1:5 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Farnesylation, the post-translational addition of a 15-carbon isoprenyl group, alters the function of several proteins, including Ras proteins.[1,2] LB 42708 is a potent inhibitor of farnesyltransferase (FTase), blocking farnesylation of H-Ras, N-Ras, and K-Ras4B with IC_{50} values of 0.8, 1.2, and 2.0 nM, respectively.[3] It displays over 50,000-fold selectivity for FTase over geranylgeranyltransferase I.[3] LB 42708 prevents the farnesylation of H-Ras in response to LPS plus IFN-γ (IC_{50} = 10 nM), preventing activation of NF-κB as well as downstream signaling.[3] These effects are obtained both in RAW 264.7 mouse macrophages and in mice.[3] LB42708 also inhibits Ras-dependent signaling in endothelial cells, stopping VEGF-mediated angiogenesis both *in vitro* and *in vivo*.[4]

References

1. Appels, N.M.G.M., Beijnen, J.H., and Schellens, J.H.M. Development of farnesyl transferase inhibitors: A review. *Oncologist* **10(8)**, 565-578 (2005).
2. Berndt, N., Hamilton, A.D., and Sebti, S.M. Targeting protein prenylation for cancer therapy. *Nat. Rev. Cancer* **11(11)**, 775-791 (2011).
3. Na, H.J., Lee, S.J., Kang, Y.C., *et al.* Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppression of p21ras-dependent NF-κB activation. *J. Immunol.* **173(2)**, 1276-1283 (2004).
4. Kim, C.K., Choi, Y.K., Ha, K.S., *et al.* The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways. *Mol. Pharmacol.* **78(1)**, 142-150 (2010).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM